Okayama University Medical Research Updates （OU-MRU） Vol.50
February 27, 2018
Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 27 February 2018
Okayama University research: Iron removal as a potential cancer therapy
(Okayama, 27 February) Researchers at Okayama University report in Oncotarget a promising method for targeting cancer stem cells that cause tumor growth and cancer relapse. The approach involves administering molecules that capture iron, an overload of which is known to be a potential cause of cancer.
Cancer stem cells (CSCs) are similar to normal stem cells in that they can differentiate — become cells of a specialized type. CSCs are resistant to radio- and chemotherapy and are believed to play an important role in metastasis and cancer relapse. Since iron overload is known to cause certain types of cancer, Dr. Toshiaki Ohara and Dr. Takayuki Ninomiya from Okayama University and colleagues have now tested whether the suppressing of iron levels can halt proliferation and ‘stemness’ of CSCs. The researchers found that controlled iron depletion indeed has the potential to become a therapy for targeting CSCs.
Dr. Ohara and colleagues first confirmed that in vitro, a supply of iron leads to the proliferation of CSCs, as well as the persistence of their stemness. Then, the researchers studied the effect of administering iron chelators: organic compounds that bond to particular metals, in this case iron. The scientists reckoned that through chelation, iron atoms are isolated and, potentially, ‘neutralized’. Two known iron chelators were tested: deferasirox and deferoxamine. Both compounds suppressed the proliferation of a set of mouse cancer cells. The associated fibroblasts (cells that play a key role in cancer progression and believed to originate from CSCs), however, were not affected.
Regarding the mechanism causing the suppression of CSC proliferation, Dr. Ohara and colleagues found that the iron chelators induced apoptosis (a highly regulated process leading to cell death). The scientists also studied the effect of deferasirox and deferoxamine on the CSCs’ stemness, and observed that the expression of stemness markers was suppressed — indirect evidence for stemness loss. The latter property was not observed in chemotherapy treatment, indicating the unique function of iron chelators as stemness marker suppressors. Finally, the researchers tested the effect of deferasirox and deferoxamine in vivo; both iron chelators suppressed CSC tumor growth and stemness marker expression.
The results of Dr. Ohara and colleagues show that the use of iron chelators could develop into an effective cancer treatment, complementary to standard chemotherapy. In the words of the researchers: “Although … the mechanisms [of stemness marker expression] are currently unknown … this study may represent an important first step in the development of novel iron chelation based strategies for CSC therapy.”
Cancer stem cells
A cancer stem cell (CSC) is a cancerous cell with the property of a normal stem cell that it can differentiate in various cell types found in a particular cancer sample. CSCs are tumor-forming, and cancer therapies targeting them are being developed, as CSCs are involved in
cancer metastasis and tumor relapse.
Dr. Ohara from Okayama University and colleagues have now shown that controlled iron
depletion in tumors is a promising novel strategy for targeting CSCs.
Chelation is a type of bond between metal ions and molecules or molecular ions. It involves a multiple-bonded ligand binding to the metal ion; the ligand is usually an organic compound and called a chelant or chelator.
Since iron overload in the human body can lead to the formation of free radicals, which in turn can cause cancer, Dr. Ohara and colleagues investigated whether iron depletion through chelation, using the iron chelators deferasirox and deferoxamine, can suppress the proliferation and stemness of cancer stem cells.
Takayuki Ninomiya, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Ryoichi Katsube, Hajime Kashima, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Ling Chen, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa & Toshiyoshi Fujiwara. Iron depletion is a novel therapeutic strategy to target cancer stem cells. Oncotarget, 12 October 2017.
Reference (Okayama University e-Bulletin & OU-MRU) : Assistant Professor Ohara’s team
OU-MRU Vol.22：Medical supportive device for hemodialysis catheter puncture
Assistant Professor Toshiaki Ohara, M.D., Ph.D.
Department of Pathology & Experimental Medicine,
Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences, Okayama University, Shikata-cho 2-5-1, Okayama
city, Okayama 700-8558, Japan
For inquiries, please contact us by replacing (a) with the @ mark.
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYIOkayama University Image Movie (You Tube): https://www.youtube.com/watch?v=KU3hOIXS5kk
Okayama University Medical Research Updates （OU-MRU）Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.2：Ensuring a cool recovery from cardiac arrestVol.3：Organ regeneration research leaps forwardVol.4：Cardiac mechanosensitive integratorVol.5：Cell injections get to the heart of congenital defectsVol.6：Fourth key molecule identified in bone developmentVol.7：Anticancer virus solution provides an alternative to surgeryVol.8：Light-responsive dye stimulates sight in genetically blind patientsVol.9：Diabetes drug helps towards immunity against cancerVol.10：Enzyme-inhibitors treat drug-resistant epilepsyVol.11：Compound-protein combination shows promise for arthritis treatmentVol.12：Molecular features of the circadian clock system in fruit fliesVol.13：Peptide directs artificial tissue growthVol.14：Simplified boron compound may treat brain tumoursVol.15：Metamaterial absorbers for infrared inspection technologiesVol.16：Epigenetics research traces how crickets restore lost limbsVol.17：Cell research shows pathway for suppressing hepatitis B virusVol.18：Therapeutic protein targets liver diseaseVol.19：Study links signalling protein to osteoarthritisVol.20：Lack of enzyme promotes fatty liver disease in thin patientsVol.21：Combined gene transduction and light therapy targets gastric cancerVol.22：Medical supportive device for hemodialysis catheter punctureVol.23：Development of low cost oral inactivated vaccines for dysenteryVol.24：Sticky molecules to tackle obesity and diabetesVol.25：Self-administered aroma foot massage may reduce symptoms of anxietyVol.26：Protein for preventing heart failureVol.27：Keeping cells in shape to fight sepsisVol.28：Viral-based therapy for bone cancerVol.29：Photoreactive compound allows protein synthesis control with lightVol.30：Cancer stem cells’ role in tumor growth revealedVol.31：Prevention of RNA virus replicationVol.32：Enzyme target for slowing bladder cancer invasionVol.33：Attacking tumors from the insideVol.34：Novel mouse model for studying pancreatic cancerVol.35：Potential cause of Lafora disease revealedVol.36：Overloading of protein localization triggers cellular defectsVol.37：Protein dosage compensation mechanism unravelledVol.38：Bioengineered tooth restoration in a large mammalVol.39：Successful test of retinal prosthesis implanted in ratsVol.40：Antibodies prolong seizure latency in epileptic miceVol.41：Inorganic biomaterials for soft-tissue adhesionVol.42：Potential drug for treating chronic pain with few side effectsVol.43：Potential origin of cancer-associated cells revealedVol.44：Protection from plant extractsVol.45：Link between biological-clock disturbance and brain dysfunction uncoveredVol.46：New method for suppressing lung cancer oncogeneVol.47：Candidate genes for eye misalignment identified
Vol.48：Nanotechnology-based approach to cancer virotherapy
Vol.49：Cell membrane as material for bone formation